Stockpicks on 18 Oct 2000 04:12:34 -0000

[Date Prev] [Date Next] [Thread Prev] [Thread Next] [Date Index] [Thread Index]

[Nettime-bold] DNAP- Could this be the next high flying biotech Stock!!

More great News for DNAP!! 10/17/00 (after company facts)

Dnaprint (DNAP) is an emerging biotech company and is trading under $1 !!!

1) CEO (Dr. Tony Frudakis) Lead scientist for Corixa starts his own company a 
   few months ago
2) Company is formed by a reverse merger of a pinksheet company

3) DNAP has already completed the accounting to get off the pinksheets and 
   should be listed on the OTCBB soon.

4) Dr. Frudakis was  responsible for a patent that sold for $54,000,000 to 
   Smith Kline Beecham while he was at Corixa.
5) Corixa's stock has gone from 14 Cents a few years ago to 50 Dollars today.
6) According to the Barron's article (9/25/00 pg 52), Dnaprint is in the late stages of forming 
   strategic alliances with major companies.

DNAP DNAPrint genomics Announces Merger 


SARASOTA, Fla., Oct 17, 2000 (BUSINESS WIRE) -- DNAPrint genomics, Inc., (Pink 
Sheets:DNAP), today announced that it has merged with an SEC 12g full reporting 
company, SDE Holdings 1, Inc., after acquiring all of the issued and outstanding 
stock of SDE. The merger allows DNAPrint genomics, Inc. to file its 211 
application with the NASD as a successor full reporting company to become listed 
on the OTC Bulletin Board. DNAPrint expects to file its 8-k 12g3 within the next 
few days, and will apply to the NASD immediately after that filing. 

About DNAPrint Genomics, Inc. 

DNAPrint genomics, Inc. provides practitioners of genomic research and 
personalized medicine with a comprehensive system for complex trait dissection 
and patient classification. DNAPrint genomics Inc. was founded by a group of 
scientists with research and commercial experience in high-level mathematical 
modeling, programming and molecular genetics. For more information about the 
company, please visit 

All statements in this press release that are not historical are forward-looking 
statements within the meaning of Section 21E of the Securities Exchange Act as 
amended, including statements regarding DNAPrint's ability to conduct high 
throughput genotyping using Orchid's SNPstream 25K platform and SNPware kits and 
the potential for use of Orchid's automated systems by developing companies. 
Such statements are subject to risks and uncertainties that could cause actual 
results to differ materially from those projected, including, but not limited 
to, uncertainties relating to technologies, product development, manufacturing, 
market acceptance, cost and pricing of Orchid products, dependence on 
collaborations and partners, regulatory approvals, competition, intellectual 
property of others, and patent protection and litigation. These and other risk 
factors are discussed in the Company's Registration Statement on Form S-1 
declared effective by the Securities and Exchange Commission on May 4, 2000. 
Orchid expressly disclaims any obligation or undertaking to release publicly any 
updates or revisions to any forward-looking statements contained herein to 
reflect any change in Orchid's expectations with regard thereto or any change in 
events, conditions, or circumstances on which any such statements are based. 

Nettime-bold mailing list